|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/15/22 Abbott Laboratories 8-K:5,9 9/15/22 12:425K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 33K 2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 147K 7: R1 Cover HTML 53K 10: XML IDEA XML File -- Filing Summary XML 12K 8: XML XBRL Instance -- tm2225651d1_8k_htm XML 20K 9: EXCEL IDEA Workbook of Financial Reports XLSX 8K 4: EX-101.DEF XBRL Definitions -- abt-20220915_def XML 78K 5: EX-101.LAB XBRL Labels -- abt-20220915_lab XML 105K 6: EX-101.PRE XBRL Presentations -- abt-20220915_pre XML 74K 3: EX-101.SCH XBRL Schema -- abt-20220915 XSD 13K 11: JSON XBRL Instance as JSON Data -- MetaLinks 28± 36K 12: ZIP XBRL Zipped Folder -- 0001104659-22-100434-xbrl Zip 56K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in charter)
| i Illinois | i 1-2189 | i 36-0698440 | ||
| (State or other Jurisdiction | (Commission File Number) | (IRS Employer | ||
| of Incorporation) | Identification No.) |
i Abbott Park, i Illinois i 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: ( i 224) i 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) |
Name of Each Exchange
on |
| i Common Shares, Without Par Value | i ABT | i New
York Stock Exchange i Chicago Stock Exchange, Inc. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 15, 2022, Claire Babineaux-Fontenot was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On September 15, 2022, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons, effective as of September 15, 2022. Abbott’s by-laws previously provided that the Board of Directors consisted of twelve persons.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Exhibit |
| 3.1 | By-Laws of Abbott Laboratories, as amended and restated effective September 15, 2022. |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |
C:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBOTT LABORATORIES | ||
| Date: September 15, 2022 | By: | /s/ Robert E. Funck, Jr. |
| Robert E. Funck, Jr. | ||
| Executive Vice President, Finance and Chief Financial Officer | ||
C:
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 9/15/22 | None on these Dates | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/01/22 Abbott Laboratories 10-Q 9/30/22 68:8.1M Workiva Inc Wde… FA01/FA |